1-Year and Landmark 6-12 Month Clinical Outcomes Among Patients in Complex Lesion Subsets Treated With DynamX Bioadaptor Compared to a Contemporary DES From the INFINITY-SWEDEHEART Randomized Clinical Trial

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Amgen; AstraZenca; Pfizer; Bayer AG